While some studies suggest a possible correlation between GLP-1 RAs and intestinal obstruction, others report no significant association, with discrepancies likely due to variations in study demographics, methodologies, and GLP-1 RA formulations
FDA-approved branded medications containing semaglutide or tirzepatide - Ozempic, Wegovy, Mounjaro, and Zepbound - are finished drug products approved by FDA based on applicable review standards for safety, effectiveness, and quality
GLP-1 receptor agonistssuch as semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro, Zepbound)work by mimicking hormones that regulate blood sugar, appetite, and digestion
Side effects and safety considerations Semaglutide side effects are consistent regardless of the provider prescribing it
FDA is cracking down on off-brand weight loss and diabetes drugs (CNN) The crackdown on off-brand weight loss and diabetes treatment drugs is about to take effect, meaning supplies for the treatments are likely to tighten
The gradual escalation exists because each step allows your GLP-1 receptors, your gut motility, and your neurological appetite circuits to adapt incrementally
